Immunome (IMNM) has released an update.
Immunome, Inc. has announced a follow-on public offering, partnering with top underwriting firms to sell 10 million shares at $20 each, aiming to raise $200 million before expenses. Scheduled for February 16, 2024, this move includes an option for underwriters to purchase an additional 1.5 million shares. The offering, based on a shelf registration statement with the SEC, signifies Immunome’s strategic steps in financial growth, with the underwriting agreement detailing customary terms and conditions.
For further insights into IMNM stock, check out TipRanks’ Stock Analysis page.
